NEW YORK, Aug. 21, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM) congratulates Immune Pharmaceuticals Inc., a biotechnology company, on its approval to list on The NASDAQ Capital Market. Immune previously traded on OTCQX®, the best marketplace for established U.S. and global companies operated by OTC Markets Group.
"We congratulate Immune Pharmaceuticals on the successful execution of its growth strategy and achievement of this important milestone," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "OTCQX has provided its investors with an efficient, transparent and information-rich trading market so they can easily analyze, value and trade its securities. We are proud to have helped contribute to Immune's success as a public company as it takes this next step."
"Immune Pharma went public one year ago and started trading on OTCQX. Over the past six months, we have significantly increased our daily trading volume and raised capital to prepare for execution on our clinical milestones and for up-listing. On Thursday, August 21, 2014, we will begin trading on The Nasdaq Capital Market, enabling additional investors to participate in our story," said Dr. Daniel Teper, CEO of Immune.
OTCQX is the marketplace of choice for U.S. and global companies that are looking to execute their business plans and graduate to a U.S. stock exchange listing. Immune is the sixth OTCQX company to graduate to the NYSE MKT or NASDAQ markets this year. Others include: BioPath Holdings Inc., Cellectar Biosciences Inc., Gulf Coast Ultra Deep Loyalty Trust, RXI Pharmaceuticals Corp. and S
|SOURCE OTC Markets Group Inc.|
Copyright©2014 PR Newswire.
All rights reserved